Diagnostic frontiers and treatment advances of double-expressor Lymphoma
10.3969/j.issn.1673-4130.2024.21.021
- VernacularTitle:双表达淋巴瘤的诊断前沿及治疗进展
- Author:
Rui WU
1
;
Miao ZHANG
;
Pan ZHAO
;
Xi ZHANG
Author Information
1. 川北医学院附属医院血液科,四川南充 637000
- Keywords:
double-expressor;
diffuse large B-cell lymphoma;
liquid biopsy;
immunotherapy;
tar-geted therapy
- From:
International Journal of Laboratory Medicine
2024;45(21):2668-2674
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma(DLBCL)can be cured with standard first-line immunochemo-therapy,but nearly 30％-40％of patients will still be refractory or relapsed,with double-expressor lympho-ma(DEL)accounting for about 50％of patients with relapsed/refractory DLBCL.It is important to seek diag-nostic and therapeutic strategies that improve outcomes for patients with DEL.In recent years,the application of new diagnostic techniques such as liquid biopsy technology in DLBCL has provided potential feasibility for the research and application prospects in the diagnosis and treatment of DEL.Targeted drugs combined with chemotherapy,hematopoietic stem cell transplantation,CAR-T cell therapy and other therapeutic methods have been found to bring clinical benefits to DEL patients.Therefore,this article aims to systematically review the diagnostic frontiers and treatment progress of DEL,and to prospect effective strategies for the diagnosis and treatment of DEL.
